ClinicalTrials.gg
Enrolling by invitationNCT06580041Updated Sep 5, 2025

Precision Care for Major Depressive Disorder

A Phase 4 interventional study of Pramipexole and Methylphenidate in Major Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by University of California, San Francisco. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Depressive Disorder, Major by University of California, San Francisco — 5 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · University of California, San Francisco.

Planned enrollment
4th of 16
150 · median 55
Started
2024
with 1 other
Phase 4
Only one
of the 17
Registered
15th of 17
by date

Among the 17 studies in Depressive Disorder, Major by University of California, San Francisco, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 15th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies in Depressive Disorder, Major by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depressive Disorder, Major by University of California, San Francisco, or all of them as a file.
02

Study summary

This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

Read the detailed description

This study will classify patients seen in the Depression Clinic of the UCSF Department of Psychiatry and Behavioral Sciences into one of five phenotypes (subtypes), including: 1) Anhedonia, 2) Cognitive deficits, 3) Stress sensitivity, 4) Anxious distress, and 5) Grief.

After phenotyping, participants will be randomized to receive phenotype-specific intervention (PSI) or care as usual (CAU).

03

Conditions studied

  • Major Depressive Disorder
  • Depression
  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is able to provide
  • English speaker
  • 18 years of age or older at time of consent
  • Meets criteria for Major Depressive Disorder
  • The subject meets eligibility criteria for at least one study phenotype as determined by assessments, imaging and/or clinical judgment.
  • PHQ-8 score at baseline of >= 10
  • Scheduled for or completed intake in UCSF outpatient psychiatry

Exclusion criteria

Exclusion Criteria:

  • Unstable or untreated medical or psychiatric condition based on clinical assessment by investigator(s)
  • Significant risk of suicidal or violent behavior as determined by clinical judgement
  • In the Investigators' opinion, the subject is not capable of adhering to the protocol requirements, or the subject has a history of poor or suspected poor compliance in clinical research studies, or the subject has a history of poor or suspected poor compliance to antidepressant medication or that study participation is not in their best interest (e.g., different treatment is indicated given their clinical presentation)
  • Pregnant or breastfeeding or planning to become pregnant during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Anhedonia phenotype: PSI

    Drug: Pramipexole

  • Active comparator
    Anhedonia phenotype: CAU

    Other: Care as usual (CAU) plan

  • Experimental
    Cognitive deficits: PSI

    Drug: Methylphenidate

  • Active comparator
    Cognitive deficits: CAU

    Other: Care as usual (CAU) plan

  • Experimental
    Stress sensitivity: PSI

    Behavioral: Mindfulness-based Stress Sensitivity Therapy (MBSST)

  • Active comparator
    Stress sensitivity: CAU

    Other: Care as usual (CAU) plan

  • Experimental
    Anxious distress: PSI

    Drug: Phenelzine

  • Active comparator
    Anxious distress: CAU

    Other: Care as usual (CAU) plan

  • Experimental
    Grief: PSI

    Behavioral: Complicated Grief Treatment (CGT)

  • Active comparator
    Grief: CAU

    Other: Care as usual (CAU) plan

Interventions

  • CAU plan modified to include a trial of pramipexole.

  • CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).

  • CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).

  • BehavioralMindfulness-based Stress Sensitivity Therapy (MBSST)

    CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.

  • BehavioralComplicated Grief Treatment (CGT)

    CAU plan modified to include a trial of CGT.

  • OtherCare as usual (CAU) plan

    Unmodified CAU plan.

06

What researchers measure

Primary outcomes

  1. Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) score

    Within-phenotype and across-phenotype contrasts.

    Time frame: Up to 24 weeks after randomization.

Secondary outcomes

  1. Snaith-Hamilton Pleasure Scale (SHAPS) score

    For anhedonia phenotype only.

    Time frame: Up to 24 weeks after randomization.

  2. Clinically Useful Depression Outcome Scale Anxious Distress Specifier Subscale (CUDOS-A) score

    For anxious distress phenotype only.

    Time frame: Up to 24 weeks after randomization.

  3. Generalized Anxiety Disorder 7-item (GAD-7) score

    For anxious distress phenotype only.

    Time frame: Up to 24 weeks after randomization.

  4. Inventory of Complicated Grief (ICG) score

    For grief phenotype only.

    Time frame: Up to 24 weeks after randomization.

  5. Perceived Deficits Questionnaire - Depression (PDQ-D) score

    For cognitive deficits phenotype only.

    Time frame: Up to 24 weeks after randomization.

  6. Patient Health Questionnaire - 8 (PHQ-8) score

    Within-phenotype and across-phenotype contrasts.

    Time frame: Up to 24 weeks after randomization.

  7. WHO Disability Assessment Schedule (WHODAS 2.0)

    Within-phenotype and across-phenotype contrasts.

    Time frame: Up to 24 weeks after randomization.

  8. Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) response

    50% reduction from baseline score. Within-phenotype and across-phenotype contrasts.

    Time frame: Up to 24 weeks after randomization.

  9. Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) remission

    Score \< 6. Within-phenotype and across-phenotype contrasts.

    Time frame: Up to 24 weeks after randomization.

07

Study locations

1 site
  • Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco
    San Francisco, California 94107, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2029, 57 months after the start.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 57 months is above that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Nov 12, 2024
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06580041
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Nov 12, 2024
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Sep 5, 2025

Study contacts

Andrew D. Krystal, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pramipexole · Methylphenidate · Phenelzine

Start the discussion